Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetyl-L-carnitine for MCI in Chronic Cerebrovascular Disease
NCT04346862Phase 4Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Acetyl-L-carnitine with Placebo (2 arms). Primary endpoints: Interference score using Korean-Color Word Stroop Test at 24 weeks and Montreal Cognitive Assessment Korean at 24 weeks. Status: unknown.
02
Drugs
acetyl-l-carnitine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04346862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346862.